Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27337224
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27337224
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Epigenomics
2016 ; 8
(6
): 831-42
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
The promise of epigenomic therapeutics in pancreatic cancer
#MMPMID27337224
Lomberk GA
; Iovanna J
; Urrutia R
Epigenomics
2016[Jun]; 8
(6
): 831-42
PMID27337224
show ga
Pancreatic ductal adenocarcinoma (PDAC) is often viewed to arise primarily by
genetic alterations. However, today we know that many aspects of the cancer
phenotype require a crosstalk among these genetic alterations with epigenetic
changes. Indeed, aberrant gene expression patterns, driven by epigenetics are
fixed by altered signaling from mutated oncogenes and tumor suppressors to define
the PDAC phenotype. This conceptual framework may have significant mechanistic
value and could offer novel possibilities for treating patients affected with
PDAC. In fact, extensive investigations are leading to the development of small
molecule drugs that reversibly modify the epigenome. These new 'epigenetic
therapeutics' discussed herein are promising to fuel a new era of studies, by
providing the medical community with new tools to treat this dismal disease.